Kailera Therapeutics and Hengrui Pharma are stepping into the obesity ring with strong Phase II data for their dual agonist of GLP-1 and GIP for overweight and obesity HRS9531, also known as KAI-9531, which Hengrui is moving through Phase III development in China and which they plan to develop in a global Phase III program as well. The companies see the potential for potentially greater weight loss given the lack of a plateau at 36 weeks.
Key Takeaways
- Kailera/Hengrui announced topline results from a Phase II study of their dual GLP-1/GIP receptor agonist HRS9531 showing 22.8% mean weight loss from baseline at 36...
Boston-based Kailera and Hengrui, based in Lianyungang, China, announced 13 January topline data from the 8mg dose of Hengrui’s Phase II trial of the drug.